Omega Funds
Overview
Omega Funds is a venture capital firm based in Boston, Massachusetts, that focuses on healthcare, technology and life science sectors across North America and Europe . They invest in companies across all growth stages in multiple therapeutic areas, including oncology, immunology, rare diseases, and precision medicine .
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Morphic | Sep 2018 | Series B | Lead |
| Alumis Inc | Mar 2024 | Series C | Co-investor |
| Beta Bionics | Nov 2024 | Series E | Co-investor |
| Bicara Therapeutics | Dec 2023 | Series C | Co-investor |
| Zhejiang Weimeng Hospital Management Co., Ltd. | Jun 2019 | Series C | Co-investor |
For institutional investors. Book with your work email.
Key People
John Maraganore
Venture Partner
Maria Koehler
Venture Partner
Mene Pangalos
Venture Partner
Sanjaya Singh
Venture Partner
Michelle Doig
Partner, Head of Corporate Development
Vincent Ossipow
Partner, Partner at Omega Funds
Gilchrist DiPrete
Director, Investor & Portfolio Analytics
Sean Cumiskey
Head of Investor Relations
Mike Powell
Executive Partner Venture Advisor
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Omega Funds based?
Omega Funds is headquartered in Boston, Massachusetts, United States.
When was Omega Funds founded?
Omega Funds was founded in 2004.
How many portfolio companies does Omega Funds have?
Omega Funds has 125 portfolio companies in Caplight's dataset.
What are some companies in Omega Funds's portfolio?
Portfolio companies visible on Caplight include Morphic, Alumis Inc, Beta Bionics, Bicara Therapeutics, Zhejiang Weimeng Hospital Management Co., Ltd..
What was Omega Funds's most recent investment shown here?
Omega Funds's most recent investment in this portfolio sample was in Beta Bionics in 2024.
What sectors does Omega Funds focus on?
Omega Funds focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Frontier & Industrial Tech, Enterprise Software, Healthcare & Life Sciences, Energy & Sustainability, Healthcare & Life Sciences, Enterprise Software, Frontier & Industrial Tech, Healthcare & Life Sciences, Healthcare & Life Sciences, Media, Entertainment & Gaming, Frontier & Industrial Tech, Energy & Sustainability, Healthcare & Life Sciences, AI, Data & Cloud Infrastructure, Energy & Sustainability, Frontier & Industrial Tech, AI, Data & Cloud Infrastructure, Enterprise Software, Enterprise Software, Frontier & Industrial Tech, AI, Data & Cloud Infrastructure, AI, Data & Cloud Infrastructure, AI, Data & Cloud Infrastructure, Enterprise Software, Frontier & Industrial Tech, Frontier & Industrial Tech.
What company stages does Omega Funds focus on?
Omega Funds typically invests at the MultiStage stage.
What is Omega Funds's AUM?
Omega Funds's assets under management are estimated between $1.0B and $10.0B.